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followed by injection of bovine TSH before the application 
of 150 μCi (5.5 MBq)  131 I decreased serum T 4 concentrations 
below the detection limit and significantly increased pitu-
itary TSHβ concentrations. The systemic effects of induced 
hypothyroidism were shown by growth arrest and a de-
crease in liver DIO1 expression below the detection limit. 
 99m Tc-pertechnetate scintigraphy revealed absence of thy-
roidal  99m Tc-pertechnetate uptake in ablated mice. In sum-
mary, we report a revised protocol for radioiodide ablation 
of the thyroid gland in the mouse to generate an in vivo 
model that allows the study of thyroid hormone action using 
NIS as a reporter gene.  © 2015 European Thyroid Association
Published by S. Karger AG, Basel 
 Introduction 
 Mouse models of hypothyroidism increase our under-
standing of the mechanisms that regulate thyroid hor-
mone action both during normal function and disease. 
 Key Words 
 Thyroid ablation · Hypothyroidism · Mouse model · 
Radioiodide 
 Abstract 
 Due to the high variance in available protocols on iodide-131 
( 131 I) ablation in rodents, we set out to establish an effective 
method to generate a thyroid-ablated mouse model that al-
lows the application of the sodium iodide symporter (NIS) as 
a reporter gene without interference with thyroidal NIS. We 
tested a range of  131 I doses with and without prestimulation 
of thyroidal radioiodide uptake by a low-iodine diet and thy-
roid-stimulating hormone (TSH) application. Efficacy of in-
duction of hypothyroidism was tested by measurement of 
serum T 4 concentrations, pituitary TSHβ and liver deiodinase 
type 1 (DIO1) mRNA expression, body weight analysis, and 
 99m Tc-pertechnetate scintigraphy. While 200 μCi (7.4 MBq) 
 131 I alone was not sufficient to abolish thyroidal T 4 produc-
tion, 500 μCi (18.5 MBq)  131 I combined with 1 week of a low-
iodine diet decreased serum concentrations below the de-
tection limit. However, the high  131 I dose resulted in severe 
side effects. A combination of 1 week of a low-iodine diet 
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Drug-induced hypothyroidism is a commonly used ap-
proach for assessment of thyroid hormone action in ro-
dent models. An alternative approach makes use of the 
thyroid-lethal properties of the radionuclide iodide-131 
( 131 I) to induce hypothyroidism. This is based on the abil-
ity of thyroid follicular cells to transport and concentrate 
radioactive iodide due to their expression of the sodium 
iodide symporter (NIS). Several nonthyroidal organs 
physiologically express NIS, such as salivary glands, gas-
tric mucosa and lactating mammary glands, and there-
fore possess the ability to actively transport iodide. They 
do not, however, organify and store it. These characteris-
tics allow for high thyroid-specific cytotoxicity of  131 I 
with minimal side effects  [1] .
 The first report of selective destruction of thyroid tis-
sue by  131 I was published by Hamilton  [2]  in 1942. Since 
then, numerous protocols for radioiodide ablation of the 
mouse thyroid gland have been published with broad vari-
ation of the thyroid-lethal dose of  131 I administered to 
mice ranging from 28 to 1,000 μCi (1–37 MBq) in the pres-
ence or absence of stimulation of thyroidal iodide uptake 
by treatment with a low-iodine diet (LID) for 1–4 weeks 
or exogenous thyroid-stimulating hormone (TSH) appli-
cation prior to the administration of radioiodide  [3–12] . 
 We and others have shown the potential of NIS as a 
reporter gene for molecular imaging with a broad range 
of possible applications  [13–24] . In our previous work, 
the role of NIS as a reporter gene allowed noninvasive 
multimodal imaging of functional NIS expression by 
 99m Tc or  123 I scintigraphy as well as SPECT and  124 I PET 
imaging that correlated well with the results of ex vivo 
gamma counter measurements as well as NIS mRNA and 
protein analysis. Stem cells have been the focus of re-
search in gene and cellular therapies. To date, these stud-
ies have lacked detailed information about the exact in 
vivo biodistribution, survival and biological compart-
ment of these cells in tissues. Genetically engineered mes-
enchymal stem cells that express NIS allow detailed non-
invasive in vivo tracking of stem cells from their initial 
deposition to survival, migration and differentiation by 
 123 I scintigraphy/SPECT and  124 I PET, as demonstrated 
in our previous work  [17, 18] . 
 Based on these studies, we are now employing this sys-
tem to study thyroid hormone action on mesenchymal 
stem cell biology within the tumor microenvironment. In 
an effort to generate a thyroid-ablated mouse model for the 
NIS-based evaluation of thyroid hormone action avoiding 
interference with thyroidal NIS that underlies an exclusive 
regulation by TSH, in the current study we describe an ef-
fective protocol for thyroid radioiodide ablation in mice.
 Materials and Methods 
 Animals 
 Male CD1 nu/nu mice from Charles River (Sulzfeld, Germany) 
were maintained under specific pathogen-free conditions with ac-
cess to a standard nude mouse diet (2.2 mg/kg iodine; ssniff, Soest, 
Germany) or LID (<15 μg/kg iodine; ssniff) and tap water ad libi-
tum. Animals were allowed to acclimatize for 1 week prior to the 
start of treatments. At the beginning of the experiments, mice 
weighed 25–30 g with an average body weight of 26.6 ± 1.27 g 
(mean ± SD). At the end of the experiments, animals were sacri-
ficed and tissues and blood were taken for analysis. The experi-
mental protocol was approved by the regional governmental com-
mission for animals (Regierung von Oberbayern, Munich, Ger-
many).
 Thyroid Radioiodide Ablation 
 Mice were randomly assigned to different treatment groups. For 
thyroid ablation, animals received a single i.p. injection of 200 μCi 
(7.4 MBq; according to Kasuga et al.  [10] ; n = 6), 500 μCi (18.5 MBq; 
according to Gorbman  [3] ; n = 6) or 150 μCi (5.5 MBq; according 
to Abel et al.  [11]  and Barca-Mayo et al. [12] ; n = 12) of carrier-free 
 131 I in 250 μl of phosphate-buffered saline containing sodium thio-
sulfate as a reducing agent (GE Healthcare, Braunschweig, Ger-
many) or saline for control animals (n = 6 for each experiment). 
Animals that received 500 μCi of  131 I were additionally put on LID 
1 week prior to radioiodide application. Before administration of 
the 150 μCi of  131 I, mice were fed LID for 1 week and on day 8 re-
ceived an i.p. injection of 10 mIU of bovine TSH (Sigma, Munich, 
Germany) 2 h before radioiodide application. A subset of radioio-
dide-ablated animals (n = 6) received daily i.p. injections of 20 ng/g 
body weight T 4 (Sigma) starting the day after the application of  131 I. 
 Serum T 4 Measurements 
 T 4 concentrations were monitored in pooled serum samples 
from tail vein blood or in individual serum samples after sacrifice. 
Serum total T 4 concentrations were measured in duplicate by ra-
dioimmunoassay using a commercially available kit (RIA-4524; 
DRG Instruments, Marburg, Germany) according to the manufac-
turer’s instructions. The samples and calibrators were incubated 
with radiolabelled tracer in antibody-coated tubes. After incuba-
tion, the liquid was aspirated and the antibody-bound radiola-
belled tracer was counted in a gamma counter (1277 GammaMas-
ter; LKB Wallac, Turku, Finland). The limit of quantification was 
at 10 n M with an intra-assay coefficient of variation of 3.6% at 80 
n M and 1.1% at 167 n M . 
 Whole-Body Planar  99m Tc-Pertechnetate Scintigraphy 
 Two hours after i.p. injection of 500 μCi (18.5 MBq) of  99m Tc-
pertechnetate, a gamma emitter that is also transported by NIS 
 [24] ,  99m Tc-pertechnetate accumulation was assessed using a gam-
ma camera equipped with a low-energy high-resolution collimator 
(e.cam, Siemens, Munich, Germany). Imaging studies were per-
formed under inhalational anesthesia using an isoflurane vapor-
izer. Regions of interest were quantified and expressed as a fraction 
of the injected dose of applied radionuclide in the cervical region.
 RNA Extraction and Quantitative Real-Time PCR 
 After sacrifice, mouse pituitaries and livers were snap frozen on 
dry ice and stored at –80   °   C until further processing. Total RNA 
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was prepared using the RNeasy Mini Kit with QIAshredder (Qia-
gen, Hilden, Germany) according to the manufacturer’s instruc-
tions. Reverse transcription was performed using SuperScript III 
First-Strand Synthesis System (Invitrogen Life Technologies,
Karlsruhe, Germany). Quantitative real-time PCR was run in du-
plicate with the QuantiTect SYBR Green PCR Kit (Qiagen) in a 
Mastercycler ep gradient S PCR cycler (Eppendorf, Hamburg, 
Germany). Relative expression levels of pituitary TSHβ and liver 
deiodinase type 1 (DIO1) were calculated from ΔΔC t values nor-
malized to internal β-actin and 18S rRNA. The following primers 
were used:  Actb , forward 5 ′ -AAGAGCTATGAGCTGCCTGA-3 ′ , 
reverse 5 ′ -TACGGATGTCAACGTCACAC-3 ′ ;  R18s , forward 
5 ′ -CGCAGCTAGGAATAATGGAA-3 ′ , reverse 5 ′ -TCTGATC-
GTCTTCGAACCTC-3 ′ ;  Tshb , forward 5 ′ -GGGTATTGTAT-
GACACGGGATA-3 ′ , reverse 5 ′ -ATTTCCACCGTTCTGTAG-
ATGA-3 ′ ;  Dio1 , forward 5 ′ -AAGACAGGGCTGAGTTTGGG-3 ′ , 
reverse 5 ′ -TGAGGAAATCGGCTGTGGAG-3 ′ .
 Statistical Analysis 
 Every data point was generated using 3–6 mice per group. Val-
ues are reported as means ± SEM or mean fold change ± SEM. 
Statistical significance of T 4 and TSHβ concentrations were tested 
by two-tailed Student’s t tests, and statistical significance of body 
weight measurements was tested by a two-tailed Mann-Whitney 
U test ( *  p < 0.05;  * *  p < 0.01;  * * *  p < 0.001).
 Results 
 131 I Ablation and T 4 Measurements 
 Three different protocols for radioiodide ablation of 
the thyroid gland were compared with the aim of estab-
lishing a thyroid-ablated mouse model of hypothyroid-
ism. Four weeks after administration of a single dose of 
200 μCi of  131 I, serum T 4 concentrations had dropped by 
50% in ablated mice compared to untreated control ani-
mals ( fig. 1 a). 
 By increasing the  131 I dose to 500 μCi with additional 
treatment with LID for 1 week prior to  131 I application, 
serum T 4 concentrations dropped below the limit of de-
tection (<10 n M ) as early as 2 weeks after radioiodide ad-
ministration ( fig. 1 a). However, starting at approximate-
ly 1 week after ablation, mice suffered from drastic weight 
loss and heavy breathing despite T 4 supplementation in a 
subgroup of mice, and, as a result, had to be sacrificed 
( fig. 1 b). 
 The combination of 1 week of LID and stimulation 
with TSH prior to administration of 150 μCi of  131 I (LID/
TSH/150 μCi of  131 I) resulted in serum T 4 concentrations 
below the detection limit within 2 weeks after ablation 
a b c
 Fig. 1. Comparison of radioiodide thyroid ablation protocols.
 a Serum T 4 concentrations 4 weeks after injection of 200 μCi of
 131 I and 2 weeks after injection of 500 μCi of  131 I combined with 
LID compared to untreated controls. The lower  131 I dose resulted 
in a 50% reduction in serum T 4 concentrations only, while the 
higher dose decreased T 4 below the detection limit (<10 n M ;
 * * *  p < 0.001).  b Mice injected with 500 μCi of  131 I suffered weight 
loss irrespective of T 4 supplementation and had to be sacrificed, 
while untreated control mice showed continuous growth. Results 
are expressed as percent of initial body weight.  c Serum T 4 concen-
trations 2 and 10 weeks after treatment with LID/TSH/150 μCi  131 I 
compared to untreated controls and mice that additionally re-
ceived 20 ng/g body weight of T 4 . This treatment led to undetect-
able serum T 4 concentrations as early as 2 weeks after  131 I applica-
tion, which remained undetectable after 10 weeks. T 4 -supplement-
ed mice showed T 4 concentrations in the range of the concentrations 
measured in untreated and therefore euthyroid control animals 
( *  p < 0.05;  * * *  p < 0.001). 
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that remained stable until the end of the observation pe-
riod (10 weeks after ablation;  fig. 1 c). The ablated mice 
without T 4 supplementation showed only minor side ef-
fects such as absence of weight gain (fig. 3) and slower 
movement in the cage. Therefore, all further experiments 
were conducted following this protocol. Serum T 4 con-
centrations in the subgroup of mice that received T 4 sup-
plementation by daily i.p. injections of 20 ng of T 4 per 
gram body weight were in the same range as in the un-
treated euthyroid group of mice ( fig. 1 c). 
 Monitoring of Body Weight and Analysis of TSHβ and 
DIO1 mRNA Expression  
 The drop in serum T 4 concentrations in ablated mice 
coincided with a 48- and 45-fold increase, respectively, in 
pituitary TSHβ concentrations 2 and 10 weeks after thy-
roid ablation, compared to untreated controls ( fig. 2 ).
 As a drop in serum T 4 and elevation of pituitary TSH 
do not per se prove a systemic state of hypothyroidism, 
we additionally monitored body weight gain in ablated 
mice versus untreated control mice. Radioiodide-ablated 
mice showed an arrest in growth from around 1 week af-
ter  131 I injection, while untreated control animals contin-
ued to grow throughout the observation period ( fig. 3 ). 
We also investigated expression of DIO1 in the liver as a 
second marker for systemic hypothyroidism. Four weeks 
after  131 I application, liver DIO1 mRNA concentrations 
dropped below the detection limit with C t values >40, 
whereas for control animals a mean C t value of 26.11 ± 
0.69 was measured with comparable reference gene con-
centrations between the two treatment groups.
 99m Tc-Pertechnetate Whole-Body Imaging 
 To examine the effects of  131 I ablation on thyroidal
radioiodide uptake, we monitored  99m Tc-pertechnetate 
biodistribution by gamma camera imaging. Significant 
 99m Tc-pertechnetate accumulation was observed in tis-
sues that physiologically express NIS, i.e. thyroid, salivary 
glands and stomach, as well as the urinary bladder due to 
renal elimination of the radionuclide ( fig. 4 ). Four weeks 
after  131 I injection,  99m Tc-pertechnetate uptake was 
strongly reduced in the cervical region of ablated mice 
with a remaining  99m Tc-pertechnetate uptake of approxi-
mately 3–5%, which was caused by the salivary glands 
that in mice are localized in the direct neighborhood of 
the thyroid gland and physiologically express NIS ( fig. 4 a) 
 [25] . In comparison, untreated control mice accumulated 
approximately 35–40% of the injected dose in the cervical 
region ( fig. 4 b).
 Discussion 
 The aim of the current study was to generate a mouse 
model in which endogenous thyroid hormone produc-
tion is abolished to create an experimental paradigm with 
 Fig. 2. Pituitary TSHβ mRNA expression. 2 and 10 weeks after 
LID/TSH/150 μCi  131 I treatment, pituitary TSHβ mRNA concen-
trations were increased significantly 48- and 45-fold, respectively, 
compared to untreated control mice ( * *  p < 0.01;  * * *  p < 0.001). 
conc. = Concentration. 
 Fig. 3. Body weight analysis. While control animals continued to 
grow throughout the observation period, LID/TSH/150 μCi  131 I-
treated mice showed growth arrest starting from around 1 week 
after thyroid ablation (day 0). Results are expressed as percent of 
initial body weight ( * *  p < 0.01). 
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a defined baseline for the evaluation of response to thy-
roid hormone that at the same time allows for the use of 
NIS as a reporter gene. While treatment of mice with an-
tithyroid drugs in drinking water is a widely used ap-
proach to render mice hypothyroid, mice have to be treat-
ed throughout the experiment, a certain degree of vari-
ability remains due to differences in water intake and 
potential side effects of the drugs have to be taken into 
consideration  [26, 27] . Furthermore, as this approach 
typically relies on a combination of thioamides (methim-
azole or propylthiouracil) that have been shown to affect 
thyroidal NIS expression  [28] , as well as the NIS-specific 
inhibitor perchlorate to block thyroid hormone synthe-
sis, the use of NIS as a reporter gene to study thyroid hor-
mone action is limited in this setting.
 For these reasons, a reliable method of thyroid radio-
iodide ablation was developed in mice that exploits the 
ability of NIS to transport  131 I. This eliminates interfer-
ence of reporter gene activity from thyroidal NIS that is 
exclusively regulated by TSH and therefore affected by 
the thyroid hormone status of the mouse. A literature 
search revealed a variety of protocols  [3–12] . As the 
‘American Thyroid Association Guide to investigating 
thyroid hormone economy and action in rodent and cell 
models’  [29] had just been published, we initially tested 
the protocol described there  [10] . Here the recommended 
 131 I dose of 200 μCi was not sufficient to completely abol-
ish endogenous thyroid hormone production. This was 
most likely due to insufficient accumulation of radioio-
dide in the thyroid, as mice were fed standard chow con-
taining 2.2 mg/kg iodine, which competes with radioio-
dide for thyroidal uptake. We therefore increased the 
amount of  131 I to 500 μCi, a dose that was reported by 
Gorbman  [3] to destroy thyroid tissue within 24 days af-
ter radioiodide application. In addition, we pretreated 
mice with LID for 1 week prior to  131 I application to de-
crease thyroidal iodine content and increase thyroidal 
NIS expression to enhance the uptake of radioiodide into 
thyroid follicular cells. This treatment decreased serum 
T 4 concentrations below the detection limit. However, 
mice showed severe side effects, i.e. drastic weight loss 
and breathing difficulties, starting from around 1 week 
after iodide injection irrespective of T 4 supplementation, 
and had to be sacrificed prematurely. We assume that the 
relatively high dose of  131 I, while specifically concentrated 
in the thyroid, caused severe damage to the thyroid-sur-
rounding tissues, in particular the radiation-sensitive tra-
chea. Due to the close proximity of these tissues to the 
thyroid and the thyroid’s small size, the β-particles emit-
ted by  131 I that have a path length of up to 2.4 mm in tis-
sue  [30] can cause lesions in the trachea, recurrent laryn-
geal nerve and parathyroid glands, as was observed by 
Gorbman  [4] . Furthermore, transient NIS-mediated 
transport of high doses of radioiodide across epithelia in 
the gastrointestinal tract may impair their function and 
lead to subsequent damage.
 To avoid the aforementioned problems, we adapted 
protocols published by Abel et al.  [11] and Barca-Mayo et 
al.  [12] , where relatively low doses of  131 I were reported 
to be sufficient for total ablation of the thyroid gland un-
der stimulation of  131 I uptake. We decided on a protocol 
consisting of 1 week of LID, followed by an injection of 
bovine TSH on day 8, 2 h before injection of 150 μCi of 
 131 I. We showed the efficacy of this protocol in inducing 
hypothyroidism in mice at the level of (1) the first indica-
tors of a disruption of thyroid function, i.e. serum T 4 con-
centrations and pituitary TSHβ content, (2) indicators of 
systemic hypothyroidism, i.e. growth arrest and decrease 
in liver DIO1 concentrations, and (3) the thyroid itself by 
 99m Tc-pertechnetate gamma camera imaging.
 Two weeks after thyroid ablation, serum T 4 concentra-
tions had dropped below the detection limit and, as ex-
pected, pituitary TSHβ concentrations reactively in-
creased 48-fold compared to untreated control mice. At 
the end of the observation period, 10 weeks after thyroid 
ablation, T 4 concentrations remained undetectable and 
ba
 Fig. 4. Whole-body  99m Tc-pertechnetate scintigraphy. 4 weeks af-
ter LID/TSH/150 μCi  131 I treatment,  99m Tc-pertechnetate gamma 
camera imaging showed strongly reduced  99m Tc-pertechnetate up-
take in the neck region of ablated animals (approx. 3–5 %;  a ) com-
pared to untreated control animals ( b ). A representative image for 
both ablated mice and control mice is shown. SG = Salivary glands. 
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TSHβ concentrations remained high. As growth hor-
mone secretion is thyroid hormone sensitive in rodents 
 [31] , ablated mice showed an arrest in growth as a conse-
quence of decreasing serum thyroid hormone concen-
trations, indicating systemic hypothyroidism. Another 
marker for systemic thyroid hormone status is liver DIO1, 
which is downregulated in hypothyroidism  [32] . Four 
weeks after thyroid ablation, liver DIO1 mRNA concen-
trations had dropped below the detection limit. Gamma 
camera imaging revealed a significant reduction in  99m Tc-
pertechnetate uptake in the cervical region 4 weeks after 
thyroid ablation, despite maximal TSH stimulation due 
to thyroid hormone deficiency in ablated animals. The 
low residual uptake originates from salivary glands that 
also physiologically express NIS  [25, 33] . In mice, the sub-
mandibular-sublingual salivary gland complex is rela-
tively large in relation to the thyroid and is located in the 
ventral cervical region in the direct neighborhood of the 
thyroid, therefore causing an overlapping signal on  123 I or 
 99m Tc-pertechnetate scintigraphies  [34] . As salivary 
glands do not possess the ability to organify iodine, reten-
tion time of the thyroid-ablative dose of  131 I is limited. 
Thus, salivary glands are preserved, at least in part, as is 
their ability to accumulate  99m Tc-pertechnetate, while 
thyroidal uptake is completely eliminated, as was shown 
by whole-body and neck transaxial planar SPECT imag-
ing by Choi et al.  [35] .
 In conclusion, our data provide an effective protocol 
for radioiodide ablation of the thyroid gland that renders 
mice hypothyroid within the course of 2 weeks and abol-
ishes thyroidal radioiodide uptake. Based on our findings, 
we recommend stimulation of NIS-mediated thyroidal 
iodide uptake by pretreatment with LID and TSH appli-
cation to help deliver a well-tolerated dose of 150 μCi of 
 131 I to mice for successful ablation of the thyroid gland. 
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